Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 183-189

  Doehn, Christian ^a   Kausch, Ingo ^a   Böhmer, Torsten ^a   Sommerauer, Martin ^a   Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PROSTATE CANCER VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CLINICAL TRIAL; FOWLPOX VIRUS; HUMAN; INJECTION SITE REACTION; NONHUMAN; PROSTATE CARCINOMA; REVIEW; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; PATENTS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

FOWLPOX VIRUS; VACCINIA VIRUS;

EID: 34247246801     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. 289122 A phase I trial of recombinant vaccinia virus, PROSTVAC, that expresses prostate specific antigen as a vaccine in men with advanced prostate cancer. Eder JP, Kantoff PW, Bubley GJ, Conner LA PROC AM SOC CLIN ONCOL 1998 34 Abs 1672
2. 328379 A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA), in advanced prostate cancer. Eder JP, Kantoff PW, Roper K, GuangXian X, Oh WK, Bubley G, Kaufman D, Panacali D, Tsang A, Schlom J, Kufe DW PROC AM SOC CLIN ONCOL 1999 18 15-18 Abs 1692
3. 336693 Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C, Sanda MG CURR OPIN MOL THER 1999 1 4 471-479
4. 338704 A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA INT J CANCER 1995 63 2 231-237
5. 338851 A phase I study of recombinant vaccinia virus (RV) that expresses prostate specific antigen (PSA) in adult patients (pts) with adenocarcinoma of the prostate. Chen AP, Bastian A, Dahut W, Chung Y, Tsang K, Khleif S, Blake K, Gelmann E, Marshall J, Schlom J, Allegra C et al PROC AM SOC CLIN ONCOL 1998 17 Abs 1209
6. 361409 A triad of costimulatory molecules synergize to amplify T-cell activation. Hodge JW, Sabzevari H, Gomez YA, Gritz L, Lorenz MGO, Schlom J CANCER RES 1999 59 22 5800-5807
7. 366068 Prostate cancer vaccine shows good phase I results. Therion Biologics Corp PRESS RELEASE 2000 11 May
8. 381596 NCI sponsors additional phase II trials for Therion's PROSTVAC VF. Therion Biologics Corp PRESS RELEASE 2000 08 September
9. 382760 Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE UROLOGY 1999 53 2 260-266
10. 391184 Gene therapy for prostate cancer: Where are we now? Steiner MS, Gingrich JR J UROL 2000 164 4 1121-1136
11. 408573 Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: Implications for clinical genetic vaccine development. Charles LG, Xie YC, Restifo NP, Roessler B, Sanda MG WORLD J UROL 2000 18 2 136-142
12. 414631 Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW CANCER RES 2001 61 11 4497-4505
13. 414643 Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY CANCER RES 2001 61 9 3725-3734
14. 452851 A Phase 2 study of a prostate specfic antigen (PSA)-based vaccine in patients (pts) with localizes prostate cancer (PC) receiving standard radiotherapy (RT). Gulley JL, Arlen PM, Bastian A, Coleman N, Hamilton M, Tsang K, Dahut WL PROC AM SOC CLIN ONCOL 2002 21 2 Abs 1814
15. 453817 Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer: Preliminary results of ECOG 7897, a randomized phase II clinical trial. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko Y-J, Williams SD, Whiteside T, Schlom J, Wilding G, Weiner LM PROC AM SOC CLIN ONCOL 2002 21 1 Abs 12
16. 464158 Therion Biologics licenses ICAM-1 from Boehringer Ingelheim. Therion Biologics Corp PRESS RELEASE 2002 September 17
17. 465287 Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton JM PROSTATE 2002 53 2 109-117
18. 465288 Tumor vaccines for the management of prostate cancer. Tumor vaccines for the management of prostate cancer. McNeel DG, Disis ML ARCH IMMUNOL THER EXP 2000 48 2 85-93
19. 467347 Technology evaluation: PROSTVAC, Therion. Doehn C, Jocham D CURR OPIN MOL THER 2002 4 5 528-534
20. 514023 Therion begins phase II clinical trial of PROSTVAC-VF as immunotherapy for prostate cancer. Therion Biologics Corp PRESS RELEASE 2003 November 19
21. 531458 A phase I trial of PROSTVAC-VF/TRICOM vaccination in patients with prostate cancer. Dipaola RS, Plante M, Petrylak D, Lattime E, Thalasila A, Manson K, Doyle-Lindrud S, Hillard B, Altscher A, Capanna T, Schuetz T et al PROC AM ASSOC CANCER RES 2004 45 Abs 4485
22. 539573 Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J J NATL CANCER INST 2000 92 15 1228-1239
23. 543549 A phase I study of sequential vaccinations with recombinant fowlpox-PSA (L155)-TRICOM (rF) alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (pts) with prostate cancer. Arlen PM, Gulley J, Dahut W, Skrupa L, Morin S, Pazdur M, Todd N, Panicali D, Tsang KY, Schlom J PROC AM SOC CLIN ONCOL 2004 23 Abs 2522
24. 550325 Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. Kaufman KL, Wang W, Manola J, DiPaola RS J CLIN ONCOL 2004 22 11 2122-2132
25. 603655 A phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). Gulley JL, Todd N, Dahut W, Schlom J, Arlen P PROC AM SOC CLIN ONCOL 2005 24 Abs 2504
26. 604625 Therapeutic vaccines for prostate cancer: A review of clinical data. Arlen PM, Gulley JL CURR OPIN INVESTIG DRUGS 2005 6 6 592-596
27. 611446 Therion's phase II PROSTVAC-VF prostate cancer study fully enrolled. Therion Biologics Corp PRESS RELEASE 2005 July 07
28. 615211 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA et al N ENGL J MED 2004 351 15 1502-1512
29. 625361 Technology evaluation: Onyvax-P, Onyvax. Doehn C, Bohmer T, Jocham D CURR OPIN MOL THER 2005 7 5 511-519
30. 673033 A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T J TRANSL MED 2006 4 1
31. 673039 Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Hodge JW, Poole DJ, Aarts WM, Gomez YA, Gritz L, Schlom J CANCER RES 2003 63 22 7942-7949
32. 673041 Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. Briones J, Timmerman JM, Panicalli DL, Levy R J NATL CANCER INST 2003 95 7 548-555
33. 676544 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM CLIN ONCOL 2006 24 19 3089-3094
34. 677451 Cancer statistics, 2006. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ CA CANCER J CLIN 2006 56 2 106-130
35. 730450 A randomized phase II trial of either vaccine therapy (recombinant pox viruses expressing PSA and the B7.1 costimulatory molecule) versus hormone therapy (nilutamide) in patients (pts) with hormone refractory prostate cancer and no radiographic evidence of disease. Arlen PA, Gulley J, Novik L, Hamilton JM, Bastian A, Pannicali D, Palena C, Tsang KY, Schlom J, Dahut WL PROC AM SOC CLIN ONCOL 2002 21 183a Abs 728
36. 730453 Immunotherapy for prostate cancer: What's the future? Arlen PM, Dahut WL, Gulley JL HEMATOL ONCOL CLIN NORTH AM 2006 20 4 965-983
37. 730458 A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldmann J, Steinberg SM et al CLIN CANCER RES 2006 12 4 1260-1269
38. 730464 Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis. Brenner H, Arndt V J CLIN ONCOL 2005 23 3 441-447
39. 730489 Phase I trial of an enhanced PSA-based vaccine and anti-CTLA-4 antibody in patients (pts) with metastatic androgen independent prostate cancer (AIPC). Gulley JL, Theoret MR, Dahut W, Pazdur M, Schlom J, Arlen PM PROSTATE CANCER SYMPOSIUM 2006 Abs 355
40. 730503 Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Huggins C, Hodges CV CANCER RES 1941 1 293-297
41. 730507 The immunotherapy of prostate and bladder cancer. Totterman TH, Loskog A, Essand M BJU INT 2005 96 5 728-735
42. 755367 Immunotherapy for prostate cancer. Karnes RJ, Whelan CM, Kwon ED CURR PHARM DESIGN 2006 12 7 807-817
43. 755369 Advances in prostate cancer chemotherapy: A new era begins. Pienta KJ, Smith DC CA CANCER J CLIN 2005 55 5 300-518
44. 755377 Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Simons JW, Sacks N UROLOGIC ONCOL 2006 24 5 419-424
45. 755490 Genetically modified viruses: Vaccines by design. Stephenson JR CURR PHARM BIOTECHNOL 2001 2 1 47-76